PTGX — Protagonist Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.84bn
- $8.05bn
- $46.02m
Protagonist Therapeutics gains as skin disease drug succeeds in study
Brief: Protagonist Therapeutics Announces Positive Topline Results For Phase 2B Frontier 1 Clinical Trial Of Oral Il-23 Receptor Antagonist JNJ-2113 (Pn-235) In Psoriasis
U.S. RESEARCH ROUNDUP-Coherent, Huntington Ingalls Industries, Spirit Aerosystems Holdings
Brief: Protagonist Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Protagonist Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Protagonist Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview
Protagonist Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Protagonist Therapeutics Inc - QTRLY Loss Per Share $0.84
Protagonist Therapeutics Inc expected to post a loss of 93 cents a share - Earnings Preview
Brief: Protagonist Therapeutics To Present Updated Phase 2 Rusfertide Clinical Results In Polycythemia Vera (Pv) At Asco 2022
U.S. RESEARCH ROUNDUP-Aerovironment, Koninklijke Ahold Delhaize NV, Walmart
Protagonist Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Protagonist Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Nasdaq Biotech Index falls, Protagonist Therapeutics top loser
Rival ulcerative colitis drug data may bode well for Morphic Holding- Jefferies
Protagonist hits near 2-year low as higher dose of bowel disease drug fails trial
U.S. STOCKS ON THE MOVE-Polaris Inc, Invesco Ltd, Corning Inc
U.S. RESEARCH ROUNDUP-Darling Ingredients, Live Nation Entertainment, Natera
Protagonist Therapeutics slumps on mixed data from bowel disease drug study